Illustration of adalimumab (blue) in the bloodstream binding tumour necrosis factor-alpha (TNF-a, orange). Adalimumab is a human monoclonal antibody that targets excess TNF-a in the body, overproduction of which causes inflammation, swelling, and pain. It is used for the treatment of autoimmune diseases such as rheumatoid and psoriatic arthritis, Crohns disease and ulcerative colitis.